Seres Therapeutics (MCRB) Consolidated Net Income: 2015-2025
Historic Consolidated Net Income for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to -$21.9 million.
- Seres Therapeutics' Consolidated Net Income fell 115.63% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.2 million, marking a year-over-year decrease of 184.78%. This contributed to the annual value of $125.9 million for FY2024, which is 64.79% up from last year.
- Per Seres Therapeutics' latest filing, its Consolidated Net Income stood at -$21.9 million for Q3 2025, which was up 10.17% from -$24.3 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Consolidated Net Income registered a high of $139.8 million during Q3 2024, and its lowest value of -$71.5 million during Q1 2023.
- Moreover, its 3-year median value for Consolidated Net Income was -$7.2 million (2024), whereas its average is -$1.1 million.
- The largest annual percentage gain for Seres Therapeutics' Consolidated Net Income in the last 5 years was 2,144.32% (2024), contrasted with its biggest fall of 334.82% (2024).
- Seres Therapeutics' Consolidated Net Income (Quarterly) stood at -$49.7 million in 2021, then skyrocketed by 95.58% to -$2.2 million in 2022, then tumbled by 197.27% to -$6.5 million in 2023, then tumbled by 334.82% to -$28.4 million in 2024, then tumbled by 115.63% to -$21.9 million in 2025.
- Its Consolidated Net Income was -$21.9 million in Q3 2025, compared to -$24.3 million in Q2 2025 and -$26.6 million in Q1 2025.